CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. (Nasdaq: PBAX) is a clinical-stage biopharmaceutical company focused on engineered T-cell receptor therapies for oncology, formed through the business combination of Phoenix Biotech Acquisition Corp and Cero Therapeutics. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Capital Corp, completed its SPAC IPO in 2021 targeting the life sciences and biotechnology sector. The combined company filed an 8-K with the SEC on April 22, 2025, under accession number 0001213900-25-033946, reflecting continued post-merger public reporting obligations. Visit SpacDesk and sign up for full access to PBAX's complete filing history, sponsor details, and deal analytics.